Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cyclophosphamide plus topotecan in treating patients who have refractory or relapsed acute myelogenous leukemia.

Key facts

Study ID

NCT00003340

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

1997-11-01

Expected to finish

2000-02-01

Last updated by the study team

2014-05-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins Oncology Center — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.